Connect with us

Hi, what are you looking for?

Thursday, Apr 9, 2026

Mugglehead Investment Magazine

Alternative investment news based in Vancouver, B.C.

Mugglehead Investment Magazine

All posts tagged "biotech"

bioAffinity Technologies soars on Monday as non-invasive lung cancer tech gains traction

bioAffinity Technologies soars on Monday as non-invasive lung cancer tech gains traction

Medical and Pharmaceutical

bioAffinity Technologies soars Monday as non-invasive lung cancer tech gains traction

Shares rose by 73% during the session with no immediate catalyst

Rowan DunneMarch 23, 2026

Immutep completely tanks after discontinuing lung cancer drug trial

Immutep completely tanks after discontinuing lung cancer drug trial

Medical and Pharmaceutical

Immutep completely tanks after discontinuing lung cancer drug trial

Shares dropped by 88% on Friday the 13th, leaving investors shook

Rowan DunneMarch 16, 2026

Kairos Pharma acquires lung cancer drug assets from Celyn Therapeutics

Kairos Pharma acquires lung cancer drug assets from Celyn Therapeutics

Medical and Pharmaceutical

Kairos Pharma acquires lung cancer drug assets from Celyn Therapeutics

Shares surged by 16% after the deal was announced

Rowan DunneMarch 2, 2026

Biotech operator Personalis sees 10% spike from Medicare covering lung cancer test

Biotech operator Personalis sees 10% spike from Medicare covering lung cancer test

Medical and Pharmaceutical

Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test

The ctDNA blood draw is known for its ultrasensitive detection capabilities

Rowan DunneFebruary 10, 2026

Pakistani cabinet approves first-ever national framework for medical cannabis regulation

Pakistani cabinet approves first-ever national framework for medical cannabis regulation

Cannabis

Pakistani cabinet approves national framework for medical cannabis regulation

The move builds on Pakistan's decision to legalize industrial hemp and medical cannabis in 2020

Rowan DunneJanuary 26, 2026

Enveric Biosciences skyrockets on patent allowance for psychedelic-inspired molecules

Enveric Biosciences skyrockets on patent allowance for psychedelic-inspired molecules

Psychedelics

Enveric Biosciences skyrockets on patent allowance for psychedelic-inspired molecules

Lead drug candidate EB-301 is structurally similar to DMT

Rowan DunneDecember 11, 2025

Eli Lilly launches AI-powered drug development platform for biotech operators

Eli Lilly launches AI-powered drug development platform for biotech operators

AI and Autonomy

Eli Lilly launches AI-powered drug development platform for biotech operators

'TuneLab' allows biotech companies to securely use Eli Lilly's AI models to gain insights about their IP

Rowan DunneSeptember 10, 2025

Pharma giant AbbVie to spend over US$1B on Gilgamesh's lead psychedelic

Pharma giant AbbVie to spend over US$1B on Gilgamesh's lead psychedelic

Psychedelics

Pharma giant AbbVie to spend over US$1B on Gilgamesh’s lead psychedelic

One of the biggest deals of all time in the industry

Rowan DunneAugust 27, 2025

Y-mAbs Stock Soars Over 100% After Acquisition Deal with SERB S.A.S.

Y-mAbs Stock Soars Over 100% After Acquisition Deal with SERB S.A.S.

Medical and Pharmaceutical

Y-mAbs stock soars over 100% after acquisition deal with SERB S.A.S.

The stock opened at USD$8.54 and traded as high as USD$8.59 before dipping briefly to USD$4.20 before ending the day at USD$8.52

Joseph MortonAugust 5, 2025

Lantern Pharma completes enrolment for Japanese lung cancer drug trial

Lantern Pharma completes enrolment for Japanese lung cancer drug trial

Medical and Pharmaceutical

Lantern Pharma completes Japanese enrolment for lung cancer drug trial

Japan has an extremely high rate of non-smokers getting diagnosed with the disease

Rowan DunneAugust 5, 2025

More Posts

Page 1 of 312 3